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HERE is increasing evidence that many of the cytokines or peptide growth factors acting on somatic or hematopoietic tissues are also expressed within the central nervous system (CNS). Their role in the embryogenesis of neural tissue, in the maintenance of its integrity in the adult, and in diseased states, including inflammatory process and neoplastic disease, has just recently been brought to light. The major source of cytokines in the CNS is the astrocyte. Normal astrocytes as well as their neoplastic counterparts, glioblastoma cells, are capable of producing a number of cytokines, including interferon (IFN)-/3, 33 interleukin (IL)-l, 34,65 granulocyte (G)-colony-stimulating factor (CSF), granulocyte-macrophage (GM)-CSF, 16,59,6~ macrophage (M)-CSF~ 15 tumor necrosis factor (TNF), 4,65 IL-6, 64 and IL-8. 63 Cytokines transmit their biological signals to responsive cells by interaction with specific high-affinity cell surface receptors, usually the adjacent cells (paracrine) or the cells producing the cytokine (autocrine). Cytokine action through the cell surface receptor further induces other cytokines, forming a complex cytokine network in the tissue. To elucidate the precise roles of these cytokines within the CNS, it is necessary to delineate the profile of receptor expression in astrocytes and glioblastoma cells. Previously, receptor expression in these cells was analyzed indirectly by observing the biological action of the cytokines or by radioreceptor assays to demonstrate binding optical density at 260-nm wavelength PCR = polymerase chain reaction R = (after cytokine name) receptor RT = reverse transcription SCF = stem cell factor TGF = transforming growth factor TNF = tumor necrosis factor sites. However, it is impossible to check for the presence of a receptor via observation of the biological response if the type of response elicited by the given cytokine receptor is unknown for the cells studied. In addition, it is difficult to screen the receptor bindings of various cell lines for a number of cytokines because the radioreceptor assay is too cumbersome. The objective of this study was to develop a molecular profile of cytokine receptor gene expression of glioblastoma multiforme cells and normal human astrocytes in vitro and in vivo using the reverse-transcription polymerase chain reaction (RT-PCR) method. 28 The profile generated via RT-PCR enables a multiparametric analysis of gene expression, which was not possible in previous study methodologies.
Materials and Methods

Glioblastoma Cells
The 16 glioblastoma cell lines (U-105 MG, U-251  MG, LNZ308, LN18, LN215, LN229, LN235, LN319,  LN340, LN382, LN428, LN443, LN444, LN464,  LN774 , and LN827) were maintained in monolayer cultures in Dulbecco's modified minimum essential medium supplemented with 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (0.1 mg/ml), and 5% to 10% heat-inactivated fetal calf serum. Each glioblastoma cell line was originally derived from explants of human glioblastoma multiforme and found negative for Mycoplasma contamination.
Normal Astrocytes
Normal adult astrocytes were derived from human brain tissue removed during surgery for a deep-seated brain tumor. Cells in the second passage were used in this study. The fetal brain astrocytes were derived from a normal human fetus aborted spontaneously at 17 weeks of gestational age; third-passage cells were uti-M. Tada, et al. lized. Both adult and fetal normal astrocytes were positive for glial fibrillary acidic protein.
Glioblastoma Tissue
Glioblastoma tissue specimens obtained at surgery were immediately frozen in liquid nitrogen and preserved at -70~ until use. The cell line LN827 and the tumor tissue sample T827 were derived from the same tumor.
Isolation of RNA
Isolation of ribonucleic acid (RNA) was performed according to the method described previously. 5 Cells were grown in culture flasks and washed twice with phosphate buffer. Glioblastoma tissue specimens (0.1 to 0.3 gin) and cultured cells (1 • 107 cells) were lysed in 4.5 ml buffer (4 M guanidine isothiocyanate, 0.5% N-lauroyl sarcosyl, 25 mM sodium citrate, and 0.1 M /3-mercaptoethanol), and homogenized with Bounce homogenizer. The lysate was supplemented with 0.5 ml of 2 M sodium acetate (pH 4.0), transferred to 15-ml polypropylate tubes and extracted with phenol/ chloroform/isoamyl alcohol, pH 4.5; RNAwas precipitated in 60% ethanol and 7.5 M ammonium acetate (volume ratio 1:20) . After the second precipitation with ethanol, the RNA pellet was washed twice with 70% ethanol and resuspended in 50 /xl diethylpyrocarbohate-treated water, analyzed via agarose gel electrophoresis, and quantified spectrophotometrically (optical density at 260-nm wavelength (OD)260/OD280).
Complementary DNA Synthesis
Total RNA was denatured at 65~ for 10 minutes immediately before RT. Reverse transcription was carried out using 10 ~xg RNA in a reaction mixture (40 p.1) containing buffer (25 mM Tris-HC1, 37.5 mM KC1, and 1.5 mM MgClz), 7.5 mM 1,4-dithiothreitol, 2 mM MgC!2, 0.5 mM each of four deoxyribonucleotide triphosphates, 0.3/xg of d(N)6 random primers, and 400 U Moloney murine leukemia virus reverse transcriptase. The reaction mixture was incubated for 60 minutes at 37~ then at 95~ for 5 minutes, followed by storage at -20~ until use.
Amplification of DNA
The receptors studied were IL-1 receptor type I (IL-1RI) 53 RT product, and 2.5 U of Thermus aquaticus deoxyribonucleic acid (DNA) polymerase. The samples were covered with two drops of mineral oil in a heating block at 94~ and amplified with a programable thermal cycler. The program was set as follows: initial melting at 94~ for 1 minute, 35 cycles of melting at 92~ for 40 seconds, annealing at 60~ or 65~ for 40 seconds, elongation at 74~ for 1.5 minutes, final elongation at 75~ for 5 minutes, and cooling to 4~ The reaction products (15/xl) were applied to a 3% NuSieve agarose gel (concentration ratio 3:1) with a DNAladder marker, stained with ethidium bromide (0.5 ~tg/ml), and photographed under ultraviolet light. Complementary DNA template (5 attomol) for each receptor was used as a positive control. Polymerase chain reaction amplification was performed at least three times using different RT products for each RNA sample.
Results
For confirmation of the purity and intactness of the extracted RNA, well-defined 18S and 28S ribosomal RNA bands were observed on gel electrophoresis for all samples studied, and 1.7 or higher A26o:A280 absorbance ratios were recorded on OD measurement (data not shown). There was complete loss of signal on electrophoresis of PCR-amplified products without the RT process, indicating that the RNA samples were free of detectable genomic DNA contamination. Every PCR amplification was performed under optimal conditions (nonspecific bands were not observed). For evaluation of the expression of each cytokine receptor gene, a single distinct band accurately corresponding to the expected amplicon size was assessed as a positive signal (Tables 2 and 3) .
Interleukin-1 Receptors
The IL-1 receptor type I (p80) transcript was positive in all 16 glioblastoma cell lines assessed and in all 11 glioblastoma tissue specimens (Fig. 1A) . Both adult and fetal normal astrocytes were positive for IL-1RI, which was also weakly expressed in normal brain tissue. The IL-1 receptor type II (p68) messenger (m)RNA was expressed in 13 of the 16 glioblastoma cell lines and in 10 of the 11 glioblastoma tissue samples (Fig. 1B) , and was positive in adult normal astrocytes but not in fetal astrocytes. Normal brain tissue also expressed IL-1RII mRNA.
Tumor Necrosis Factor Receptors
The p75TNFR mRNA was expressed in nine of the 16 glioblastoma cell lines and in nine of the 11 glioblastoma tissue samples (Fig. 1C) . The signals for the glioblastoma cell lines were weaker than those of the p55TNFR. Both adult and fetal normal astrocytes weakly expressed the mRNA. Normal brain was negative for p75TNFR mRNA. * 1L = interleukin; R = receptor; TNF = tumor necrosis factor; IFN = interferon; G = granulocyte; M = macrophage; CSF = colony-stimulating factor; SCF = stem cell factor; ++ = positive signal stronger than control; + = weaker positive signal; -= no signal.
The p55TNFR mRNA was expressed in all 16 glioblastoma cell lines and in nine of the 11 glioblastoma tissue specimens (Fig. 1D) . Adult and fetal astrocytes were also positive for p55TNFR mRNA, while normal brain tissue was weakly positive.
Interferon Receptors
The IFN-~//3 mRNAwas positive in all glioblastoma cell lines and positive in 10 of the 11 glioblastoma tissue specimens (Fig. 1E) . Both adult and fetal astrocytes also expressed IFN-c~//3R mRNA, but the signal in adult astrocytes was weak. Normal brain tissue was weakly positive.
The IFN-TR mRNA was positive in all glioblastoma cell lines and in 10 of the 11 glioblastoma tissue samples (Fig. 1F) . It was also expressed in both fetal and adult normal astrocytes, but not in normal brain tissue.
Colony-Stimulating Factor Receptors
The GM-CSFR oe subunit mRNA was positive in seven of the 16 glioblastoma cell lines and weakly positive in two of the 11 glioblastoma tissue samples (Fig.  1G) . Normal astrocytes and normal brain tissue were negative for GM-CSFR mRNA.
The G-CSFR mRNA was negative in all 16 glioblas- toma cell lines, but was positive in three of the 11 glioblastoma tissue specimens, two of which showed weaker signals (Fig. 1H) . Normal astrocytes and normal brain tissue were negative for G-CSFR mRNA.
The M-CSFR (c-fins) was positive in eight of the 16 cell lines and positive in all 11 glioblastoma tissue specimens (Fig. 1I) . Both adult and fetal astrocytes weakly expressed M-CSFR mRNA. Normal brain tissue was weakly positive.
The SCFR (c-kit) was positive in 14 of the 16 glioblastoma cell lines and in all 11 glioblastoma tissue samples (Fig. 1J) . Both adult and fetal astrocytes also expressed the SCFR mRNA. Normal brain tissue was weakly positive.
Interleukin-6 Receptors
The IL-6R mRNA was weakly positive in three of the 16 glioblastoma cell lines but was negative in all 11 glioblastoma tissue samples (Fig. 1K) . Normal astrocytes and normal brain tissue were negative for IL-6R mRNA.
Interleukin-8 Receptor
The IL-8R was expressed in only one cell line (LNZ308). Normal astrocytes and normal brain tissue were negative for IL-8R mRNA (Fig. 1L) . However, it was expressed strongly in three and weakly in six of the 11 glioblastoma tissue specimens.
Discussion
To ascertain the range of cytokine receptors that may be expressed by human glioblastoma cells, normal cultured astrocytes, and normal brain and glioblastoma tissue, we looked for the presence of mRNA transcripts for various cytokine receptors in RNA extracted from the cells. Because of the low quantity of mRNA for the cytokine receptors, it was not possible to accurately detect the mRNA by conventional Northern blot analysis. We therefore employed an RNA detection system based on the RT-PCR. With highly specific primer pairs and stringent conditions of PCR amplification in which nonspecffic priming does not take place, results of RT-PCR amplification are quite reliable for the demonstration of mRNA transcripts. This method also provides high efficiency in handling large numbers of samples with a limited quantity of RNA. Due to these advantages of the RT-PCR method, we were able to screen a substantial number of samples for the expression of various cytokine receptors. Possible autocrine and paracrine cytokine networks of glioblastoma cells and adjacent normal brain and immune cells are summarized in Fig. 2 .
Interleukin-1 Receptors
Various reactions of glioblastoma cells and astrocytes to IL-1 have been determined, including growth promotion, 21,31 up-regulation of intercellular adhesion molecules (ICAM's), 17,3~ down-regulation of HLA-DR antigens, 9 and an increase in cytokine productions, 4"6"16"55'59'63 indicating that astrocytes and glioblastoma cells possess specific receptors for IL-1. Two distinct molecules have been recognized as the major IL-1 receptors: p80 (IL-1RI) s3 and p68 (IL-1RII). 4~ The IL-1RI is consistently observed on helper T cells and fibroblasts, whereas B cell lines possess the IL-1RII. The type of IL-1R expressed on glioblastoma cells and astrocytes had not been previously defined. The present study showed that human glioblastoma cells and normal astrocytes express the genes for both types of IL-1R. However, it is noteworthy that three of 16 glioblastoma cell lines and fetal astrocytes did not express the IL-1RII, while the IL-1RI was consistently expressed. The predominance of IL-1RI in glioblastoma cell lines may be a reflection of the normal expression of this receptor in mesenchymal cells, and the lack of IL-1RII gene expression in fetal astrocytes might be related to some developmental process. Furthermore, the present in vivo expression studies showed that both IL-1 RI and IL-1 RII were positive in normal brain tissue and the majority of glioblastoma tissue samples, with stronger signals for IL-1RI, demonstrating consistency with thd in vitro expressions. Since precise functional differences between the two types of IL-1R are not well known, 11 the biological significance of the predominance of IL-1RI is unclear. Interleukin-lRI shows a greater affinity to IL-la than to IL-1/3, and IL-1RII binds best to IL-1/3. Stimulated astrocytes and glioblastoma cells are capable of producing IL-1.12'13'34'35'65 Although mRNA of both IL-la and IL-1/3 are expressed in these cells, secretion of IL-1/3 seems to be defective 34 (M Tada, unpublished data). If an IL-1 autocrine loop exists, a loop between IL-lc~ and IL-1RI is more probable than one between IL-1/3 and IL-1RII.
Tumor Necrosis Factor Receptors
There are two molecularly distinct cell membrane TNF receptors, both of which bind TNF-c~ and TNF-/3 (lymphotoxin). These receptors have different molecular weights and are referred to as p75 or p80 (p75TNFR), s4 or p55 or p60 (p55TNFR), 36 based on their size. A variety of responses of glioblastoma cells and astrocytes to TNF include growth modulation] ,2~, 31 48 49 52 17,30 , , 9 induction of ICAM-1, , up-regulation of major histocompatibility complex (MHC) molecules, 39' 72 and increased production of cytokines. 14-16,49' 51' 55' 6~ However, the type of TNFR expressed in glioblastoma cells and astrocytes is unknown. The present study showed that gene expression of p55TNFR was consistently expressed in glioblastoma cells. In contrast, the p75TNFR gene was expressed in about one-half of the cell lines with weaker signals. Fetal and adult astrocytes also expressed the p55TNFR gene prominently, whereas they expressed p75TNFR only weakly. The majority of glioblastoma tissue samples expressed both p75TNFR and p55TNFR, but the signals of p75TNFR were weaker. Normal brain tissue was positive for p55TNFR but negative for p75TNFR, indicating the predominance of p55TNFR in the normal CNS. The p55TNFR is probably responsible for mediating most of the various actions of TNF, including antiviral activity, dedifferentiation of adipocytes to fibroblasts, and induction of a panel of mRNA such as manganous superoxide dismutase, IL-6, c-fos, and nuclear factor (NF)-•B, s8 whereas the function of p75TNFR is mainly related to lymphocyte proliferation and maturation (increased expression of IL-2 receptor (Tac), GM-CSE and HLA-DR). 44,62 A recent report, however, has shown that p75TNFR mediates cytotoxicity caused by TNF. 22 The lack of cytotoxic action by TNF to glioblastoma cells 49,72 and the prominent actions in inducing various cytokines and cell surface molecules may be attributable to the scarcity of p75TNFR and the abundance of p55TNFR on glioblastoma cells. Since TNF can be produced by astrocytes or glioblastoma cells when they are stimulated, 4,6,35,65 an autocrine loop of TNF is potentially possible; however, further investigation is required.
Interferon Receptors
Interferon-c~ and IFN-13 share the same receptor, [FN-c~/13R. 61 There is some possibility that the IFNc~/13R is complex and consists of several subunits. This receptor is known to be expressed on most cells, as assessed by radioreceptor assay. 32 The present study showed that all of the glioblastoma cell lines tested and fetal and adult astrocytes expressed the IFN-~//3R gene. Both the majority of glioblastoma tissue specimens (10 of 11) and normal brain tissue expressed IFNc~//3R, showing consistency with in vitro expressions. As proof of functional receptor expression, certain biological activities of IFN-ed/3 on astrocytes or glioblastoma cells are known. On astrocytes and glioblastoma cells, IFN-/3 suppresses MHC class II expression, 3,25,45 and IFN-c~ and IFN-13 inhibit the growth of glioblastoma cells. 7.24,71 Interferon-/3 has been shown to be expressed by glioblastoma cells and astrocytes after stimulation. 33,67 Thus, an autocrine loop between IFN-13 and IFN-aJ/3R may exist, although such a loop is considered to be limited to a special situation such as an inflammatory process.
In contrast to IFN-ot and IFN-/3, a wide range of actions by IFN-~/on glioblastoma cells and astrocytes have been determined, including ICAM-I induction, 17' 3~ MHC class II induction, 25,45 and growth modulation, z3,7~ The IFN-3~ receptor is a unique cytokine receptor that has no similarities to known proteins. 1 Signal transduction requires a species-specific accessory factor located in chromosome 21q? 2 The present study demonstrated that the IFN-'),R gene was expressed in all glioblastoma cell lines tested and in normal astrocytes. The majority of glioblastoma tissue samples (10 of 11) expressed IFN-~/R, showing consistency with in vitro expressions. To our knowledge IFN-3, cannot be produced by the resident cells in the CNS but only by exogenous T lymphocytes or natural killer cells. 66 Thus, despite the abundant expression of the receptor, IFN-3, seems to act on glioblastoma cells or astrocytes only in situations where immune cells are recruited or IFN-7 was administered artificially as a biological response modifier.
Colony-Stimulating Factor Receptors
Granulocyte-macrophage CSF is known to be produced by astrocytes ~3 and glioblastoma cells. 16 The present study showed that the GM-CSFR gene is expressed in seven of 16 glioblastoma cell lines but not in astrocytes, suggesting the possibility of an autocrinc loop of GM-CSF in glioblastoma cells. However, GM-CSF is not produced in glioblastoma tissue in vivo? ~' The biological response to GM-CSF is not yet known for glioblastoma cells or astrocytes; thus, the meaning of the expression of GM-CSFR in vitro is still unclear. The absence of GM-CSFR expression in normal astrocvtes indicates that GM-CSF produced by astrocytes in ttqe CNS may act on microglial cells/macrophages or neurons, 26 rather than on astrocytes themselves. The GM-CSFR expression was negative in normal brain tissue and the majority of glioblastoma tissue samples, lending support to this hypothesis. The GM-CSF receptor (0~ subunit) shares the/3 subunit with IL-3R and IL-5R o~ subunits. ~,37 The precise role of these cytokines in the human CNS needs to be elucidated.
Granulocyte CSF has been shown to be produced by astrocytes 67 and glioblastoma cells. 59,6~ Our results demonstrated that there was no gene expression of the G-CSFR in cultured glioblastoma cells or astrocytes. Because the G-CSFR is a specific single high-affinity type of receptor, ~8 it is obvious that G-CSF produced by glioblastoma cells or astrocytes cannot act in an autocrine fashion. The production of G-CSF by astrocytes may have a certain role in inflammatory processes of the CNS 19 in a paracrine manner.
Macrophage CSFR is identical to the c-fins protooncogene product, 8 and belongs to the tyrosine kinase receptor family. Expression of the M-CSFR is thought to be restricted to cells of the mononuclear phagocyte lineage and its progenitors, 2 although the receptor has been shown to be expressed during fetal development. 46 The present study has shown that one-half of the glioblastoma cell lines expressed the M-CSFR mRNA. Furthermore, adult and fetal astrocytes also expressed the gene. In vivo studies demonstrated that normal brain tissue and all of the glioblastoma tissue specimens expressed the M-CSFR gene. Macrophage CSF is produced by astrocytes, ~5 and is found in the cerebrospinal fluid of patients with glioblastoma and bacterial men- 19 ingitis. Thus, M-CSF may act in an autocrine fashion on glioblastoma cells and astrocytes. Like other members of the tyrosine kinase receptor family, such as fibroblast growth factor and platelet-derived growth factor, M-CSF may potentially play a substantial role in the growth and progression of glioblastoma multiforme.
Stem Cell Factor Receptor
The SCFR is the c-kit proto-oncogene product, which is also a member of the tyrosine kinase receptor family. 3s'' Both SCF and SCFR (c-kit) are expressed in the mouse embryonic brain? ~ In addition, SCFR is known to be expressed in A172 human glioblastoma cells. ~9 Our present results showed that a majority of the glioblastoma cells tested and normal astrocytes expressed the SCFR gene. In vivo studies demonstrated that SCFR was positive in normal brain tissue and in all glioblastoma tissue specimens. Together, these results suggest that SCF plays certain roles in the CNS. Little is known about the biological activities of SCF on glioblastoma cells or astrocytes. Further studies should investigate the roles of this cytokine in the CNS.
Interleukin-6 Receptor
Interleuk!n-6 is known to be produced by glioblastoma cells 4~,64 and astrocytes. 14,5~,55 Although a radioreceptor assay demonstrated IL-6 binding sites on glioblastoma cells, 57 it has not been determined whether these cells possess functional 1L-6 receptors. 3~ The present study indicated that a majority of glioblastoma cells and human astrocytes did not express the IL-6R (gp80). In addition, IL-6R was negative in normal brain tissue and all glioblastoma tissue samples. The IL-6R functions as a complex of the gp80 IL-6 binding protein and the gp130 signal-transducing protein. 68 We have not yet examined the expression of gpl30 in glioblastoma cells or astrocytes. Nevertheless, it can be said that IL-6 does not act as a significant autocrine growth factor in glioblastoma cells or astrocytes.
Interleukin-8 Receptor
Interleukin-8 has been shown to be produced by glioblastoma cells, and is also found in the cerebrospinal fluid of patients with bacterial meningitis. 63 Radioreceptor assay of IL-8 binding on glioblastoma cells demonstrated no significant binding site on those ceils. Our present results showed that the majority of glioblastoma cells studied and astrocytes did not express the IL-8R; IL-SR was also negative in normal brain tissue. However, IL-8R was positive in nine of the 11 glioblastoma tissue samples. Tumor tissue contains infiltrating T !ymphocytes and granulocytes that express the IL-8R, 4",5~ and these could be a source of IL-8R mRNA. However, negative results for IL-6R and G-CSFR in glioblastoma tissue indicate that contamination of T lymphocyte-or granulocyte-derived mRNA is minimal. Further study of this IL-8R mRNA expression in vivo is necessary.
Conclusions
Expression of mRNA transcripts does not always mean protein (receptor) expression, especially when there is posttranscriptional regulation of protein synthesis. However, for the receptors studied here, it is probable that the gene expression corresponds to the protein expression, since no posttranscriptional regulation for these cytokine receptors has been described.
Among the possible autocrine mechanisms, the IL-1 autocrine loop may have a particular significance in the growth of glioblastomas, since IL-1 can directly stimulate cell proliferation 27,3t and induce the expression of many other secondary cytokines such as IL-6, 27' 64 IL-8, 63 transforming growth factor (TGF)-/3] ~ and TNF-ot. 4 In addition to their immunomodulatory actions, such as the potent immunosuppressive effect of TGF-13, these cytokines can modulate tumor growth. For instance, IL-1, u IL-6, 41 IL-8, 29 and TGF-/3247 can directly or indirectly stimulate the neovascularization of the tumor. Interleukin-1 and TGF-132 can modulate the expression of ICAM and the production of extracellular matrix components, leading to changes in the invasive behavior of the tumor cells, al,47 Thus, future therapy of glioblastomas may include a modification of the cytokine network through blocking key autocrine loops.
With recombinant proteins, cytokines such as TNF and IFN-/3 are now used in clinical trials for the treatment of glioblastomas. However, the presence of receptors for these cytokines does not readily imply their clinical efficacy. The effects of TNF and IFN-/3 are cytostatic, rather than cytotoxic, to glioblastoma cells, 23,24,49 which means that the tumor cells can survive and grow after disappearance of the cytokines. In addition, cytokines are characterized by their short lifespan and short range of action in vivo. Tumor cells can continue to grow because of the short-term and limited extent of the cytokines' action. Another rationale for the use of these cytokines might be their immunomodulatory actions. However, one must consider the untoward tumor growth-promoting effects of the secondarily induced cytokines. Overall cytokine reactions should be monitored in conjunction with the cytokine receptor expression of glioblastoma cells. 56 One should also be aware of the similarity in the profile of cytokine receptor expression between normal astrocytes and glioblastoma cells. The administered cytokine may cause similar reactions in the surrounding brain such as brain edema and inflammation (autoimmune-like reaction).
Hematopoietic cytokines such as G-CSF, GM-CSF, and SCF are often utilized to rescue decreased leukocytes during chemotherapy. When using these cytokines, one should take into consideration the receptor expression on glioblastoma cells to avoid unexpected tumor growth promotion. In this context, our methodology would be useful to evaluate the indications or contraindications of cytokine therapies. Further studies are warranted to elucidate the functional roles of the individual cytokine receptors, especially for M-CSFR and SCFR, which were demonstrated for the first time in the present study to be present on glioblastoma cells and astrocytes.
